Prophylactic Therapy in Hemophilia

Efficacy of twice weekly versus thrice weekly prophylactic factor VIII therapy in children with hemophilia A

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015235

Enrollment

Registered

2018-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- stable children with moderate or severe hemophilia without inhibitors

Interventions

Intervention1: Factor VIII: plasma derived human monoclonal purified factor VIII dose-10 IU/kg route-i.v. frequency-twice weekly total duration- 6 months to 1 year Intervention2: Factor VIII: plasma d

Eligibility

Inclusion criteria

Inclusion criteria: All patients with hemophilia A having moderate and severe hemophilia and upto 18 years of age

Exclusion criteria

Exclusion criteria: Patients having any measurable inhibitor at the start of study

Design outcomes

Primary

Measure	Time frame
Annual Bleeding RateTimepoint: At end of study	—

Secondary

Measure	Time frame
1. Preservation of index joint structure as assessed by HJHS 2.1 score 2. Improvement in daily activity as assessed by FISH score 3. Incidence of transfusion transmitted infections.Timepoint: at beginning and end of study	—

Countries

India

Contacts

Public ContactDr Gorika Singhal

UCMS and GTB Hospital

gorika.singhal@gmail.com9910027713

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026